BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25939664)

  • 21. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
    Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
    Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing.
    Wang WH; Lu MY; Tsai CH; Wang SC; Chou SW; Jou ST
    J Formos Med Assoc; 2021 Apr; 120(4):1148-1152. PubMed ID: 32933826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of splenomegaly in CBL syndrome.
    Coe RR; McKinnon ML; Tarailo-Graovac M; Ross CJ; Wasserman WW; Friedman JM; Rogers PC; van Karnebeek CDM
    Eur J Med Genet; 2017 Jul; 60(7):374-379. PubMed ID: 28414188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel, germline, deactivating CBL variant p.L493F alters domain orientation and is associated with multiple childhood cancers.
    Norris GA; Tsai AC; Schneider KW; Wu YH; Caulfield T; Green AL
    Cancer Genet; 2021 Jun; 254-255():18-24. PubMed ID: 33550024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline CBL mutation associated with a noonan-like syndrome with primary lymphedema and teratoma associated with acquired uniparental isodisomy of chromosome 11q23.
    Hanson HL; Wilson MJ; Short JP; Chioza BA; Crosby AH; Nash RM; Marks KJ; Mansour S
    Am J Med Genet A; 2014 Apr; 164A(4):1003-9. PubMed ID: 24458550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo mutations in CBL causing early-onset paediatric moyamoya angiopathy.
    Guey S; Grangeon L; Brunelle F; Bergametti F; Amiel J; Lyonnet S; Delaforge A; Arnould M; Desnous B; Bellesme C; Hervé D; Schwitalla JC; Kraemer M; Tournier-Lasserve E; Kossorotoff M
    J Med Genet; 2017 Aug; 54(8):550-557. PubMed ID: 28343148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL.
    Gagne AL; Maguire JA; Gandre-Babbe S; Chou ST; Tasian SK; Loh ML; Weiss MJ; Gadue P; French DL
    Stem Cell Res; 2018 Aug; 31():157-160. PubMed ID: 30096712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
    Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
    Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome.
    Shiba N; Kato M; Park MJ; Sanada M; Ito E; Fukushima K; Sako M; Arakawa H; Ogawa S; Hayashi Y
    Leukemia; 2010 May; 24(5):1090-2. PubMed ID: 20357823
    [No Abstract]   [Full Text] [Related]  

  • 36. Hydrops, fetal pleural effusions and chylothorax in three patients with CBL mutations.
    Bülow L; Lissewski C; Bressel R; Rauch A; Stark Z; Zenker M; Bartsch O
    Am J Med Genet A; 2015 Feb; 167A(2):394-9. PubMed ID: 25358541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
    Javadi M; Richmond TD; Huang K; Barber DL
    J Biol Chem; 2013 Jul; 288(27):19459-70. PubMed ID: 23696637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphologic and Immunophenotypic Differences in Juvenile Myelomonocytic Leukemias With CBL and Other Canonical RAS-pathway Gene Mutations: A Single Institutional Experience.
    Mariani RA; Jennings L; Zhang S; Bhat R; Gong S
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):e819-e825. PubMed ID: 33769390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations.
    Matsuda K; Taira C; Sakashita K; Saito S; Tanaka-Yanagisawa M; Yanagisawa R; Nakazawa Y; Shiohara M; Fukushima K; Oda M; Honda T; Nakahata T; Koike K
    Blood; 2010 Jul; 115(26):5429-31. PubMed ID: 20595524
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.